Clincosm LogoSign in Get a demo

XL999 Administered Intravenously to a Subject With Advanced Malignancies

Sponsor
John Sarantopoulos (Other)
Overall Status
No longer available
CT.gov ID
NCT01945164
Collaborator
(none)
1
Location
26
Duration (Months)

Study Details

Study Description

Brief Summary

Cancer is a worldwide clinical and economic problem. Conventional approaches to treating cancer include surgery, radiotherapy, and cytotoxic chemotherapy as single modalities or as combined therapies. Recently, targeted therapies including antibodies and small molecule inhibitors have also demonstrated clinical benefit. It is now possible to study different genetic lesions involved in cancer types due to advances in genomic methodologies. The investigational drug in this study, XL999 inhibits multiple receptor tyrosine kinases, including VEGF receptor (VEGFR2/KDR), platelet derived growth factor receptors (PDGFRβ), fms-like tyrosine kinase receptor 3 (FLT3), fibroblast growth factor receptors (FGFR1, FGFR3), RET, and KIT, and thus, interferes with multiple cellular processes simultaneously and will likely have effects on the integrity of tumor neovasculature and angiogenesis. Together with the ability to induce a novel cell cycle arrest, the spectrum of activities that XL999 exhibits may reduce both tumor cell proliferation and angiogenesis in the clinic.

The rationale and purpose of this maintenance study is to allow a subject receiving clinical benefit from XL999 to continue treatment.

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Expanded Access
Official Title:
Single Patient Treatment Study for the Use of XL999 Administered Intravenously to a Subject With Advanced Malignancies Previously Enrolled in Study XL999-900
Study Start Date :
Apr 1, 2010
Actual Primary Completion Date :
Jun 1, 2012
Actual Study Completion Date :
Jun 1, 2012

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • The subject is eligible to continue to receive XL999 in the absence of progressive disease and unacceptable XL999-related toxicity.
    Exclusion Criteria:
    • Progressive disease.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cancer Therapy and Research Center at UTHSCSA San Antonio Texas United States 78229

    Sponsors and Collaborators

    • John Sarantopoulos

    Investigators

    • Principal Investigator: John Sarantopoulos, MD, University of Texas Health Science Center San Antonio

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    John Sarantopoulos, Principal Investigator, The University of Texas Health Science Center at San Antonio
    ClinicalTrials.gov Identifier:
    NCT01945164
    Other Study ID Numbers:
    • CTRC 10-08
    • HSC20100312H
    First Posted:
    Sep 18, 2013
    Last Update Posted:
    Oct 21, 2014
    Last Verified:
    Oct 1, 2014
    Keywords provided by John Sarantopoulos, Principal Investigator, The University of Texas Health Science Center at San Antonio
    XL999
    Advanced Malignancy
    Additional relevant MeSH terms:
    Neoplasms

    Study Results

    No Results Posted as of Oct 21, 2014